)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
RAPT Therapeutics
RAPT Therapeutics (RAPT) investor relations material
RAPT Therapeutics 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary14 Jan, 2026
Strategic focus and pipeline development
Focused on transformative therapies for high-value inflammatory disorders, with Ozureprobart as the lead asset targeting allergic diseases.
Ozureprobart is a next-generation anti-IgE antibody designed for less frequent dosing and broader efficacy than current therapies.
Expanded pipeline includes a next-generation CCR4 antagonist and ongoing collaborations with partners in China for asthma and CSU studies.
Board and team strengthened with experienced industry leaders to support commercialization and drug development.
Completed a $265 million follow-on offering, extending cash runway to mid-2028.
Clinical progress and milestones
Phase 2b food allergy study (PRESTIGE) initiated, with top-line data expected in the first half of 2027.
Positive phase 2 results in chronic spontaneous urticaria (CSU) support initiation of phase 3 studies in both the US and China in 2024.
Partner JU in China completed a phase 2 asthma study and plans to start phase 3 trials in CSU and asthma this year.
Multiple clinical milestones anticipated over the next two years, supported by a strong cash position.
Enrollment for PRESTIGE is on track, with high investigator and patient interest across US, Canada, and Australia.
Differentiation and market opportunity
Ozureprobart offers less frequent dosing (every 8–12 weeks) compared to Omalizumab (every 2–4 weeks), reducing injection burden.
Higher potency and improved PK allow treatment of high-IgE and high-weight patients, addressing unmet needs excluded from Omalizumab label.
Market research indicates payers value the improved compliance and broader efficacy, supporting a price premium over branded Omalizumab.
Food allergy represents a $40B+ US market, with 17 million diagnosed patients and high socioeconomic burden.
Omalizumab’s rapid uptake in food allergy highlights high unmet need and commercial potential for next-generation therapies.
What is the market value of OZU's broader coverage?
Regulatory view on China CSU data for global trials
How does OZU's dosing frequency drive price premium?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next RAPT Therapeutics earnings date
Q4 20256 Mar, 2026
RAPT Therapeutics
Next RAPT Therapeutics earnings date
Q4 20256 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
RAPT Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in immunology-based treatments. The company's primary focus is on discovering, developing, and commercializing oral small molecule therapies for significant unmet needs in inflammatory diseases and cancer. Utilizing a proprietary drug discovery and development engine, RAPT Therapeutics designs highly selective small molecules aimed at modulating critical immune responses. The company's pipeline includes drug candidates targeting CCR4 and other key immune pathways, with ongoing development for conditions such as atopic dermatitis and various cancers. RAPT Therapeutics is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage